Provided by Tiger Trade Technology Pte. Ltd.

PMV Pharmaceuticals

1.04
+0.02001.96%
Post-market: 1.040.00000.00%18:51 EST
Volume:208.26K
Turnover:217.88K
Market Cap:55.34M
PE:-0.66
High:1.07
Open:1.03
Low:1.02
Close:1.02
52wk High:1.84
52wk Low:0.8100
Shares:53.21M
Float Shares:36.20M
Volume Ratio:0.69
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5845
EPS(LYR):-1.1382
ROE:-51.87%
ROA:-32.02%
PB:0.46
PE(LYR):-0.91

Loading ...

PMV Pharmaceuticals Reports Increased Quarterly Loss

TIPRANKS
·
Nov 13, 2025

Promising Developments in PMV Pharmaceuticals’ PYNNACLE Phase 2 Trial Boost Buy Rating

TIPRANKS
·
Nov 13, 2025

Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential

TIPRANKS
·
Nov 12, 2025

PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)

TIPRANKS
·
Nov 12, 2025

PMV Pharmaceuticals reports third quarter loss as cash reserves fall to $129.3 million

Reuters
·
Nov 12, 2025

BRIEF-PMV Pharmaceuticals Q3 EPS USD -0.4

Reuters
·
Nov 12, 2025

Major Stakeholder Orbimed Advisors Sells Massive PMV Pharmaceuticals Shares!

TIPRANKS
·
Oct 28, 2025

OrbiMed Advisors LLC Reports Disposal of PMV Pharmaceuticals Common Shares

Reuters
·
Oct 28, 2025

PMV Pharmaceuticals Advances Cancer Treatment with Promising Study on PC14586

TIPRANKS
·
Oct 28, 2025

PMV Pharmaceuticals announces updated rezatapopt monotherapy interim data

TIPRANKS
·
Oct 24, 2025

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

GlobeNewswire
·
Oct 24, 2025

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire
·
Oct 14, 2025

OrbiMed Advisors LLC Reports Disposal of Common Shares of PMV Pharmaceuticals Inc

Reuters
·
Sep 13, 2025

PMV Pharmaceuticals (PMVP) Gets a Buy from TD Cowen

TIPRANKS
·
Sep 11, 2025

PMV Pharmaceuticals Reports Promising Phase 2 Trial Results

TIPRANKS
·
Sep 11, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy

Reuters
·
Sep 11, 2025

PMV Pharmaceuticals Shares Rise 6.3% After Positive Cancer Therapy Trial Data

THOMSON REUTERS
·
Sep 10, 2025

PMV Pharmaceuticals Inc - Rezatapopt Nda Submission for Platinum Resistant/Refractory Ovarian Cancer Planned in Q1 2027

THOMSON REUTERS
·
Sep 10, 2025

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

GlobeNewswire
·
Sep 10, 2025

PMV Pharmaceuticals Q2 EPS USD -0.41

Reuters
·
Aug 07, 2025